CALR and neoplasm: After engineering the monobodies by grafting these peptide sequences at their binding loops (BC and FG), we characterized them for ecto-CRT targeting efficiency in vitro and in vivo after treatment of tumor-bearing mice with immunogenic and non-immunogenic anticancer agents (Scheme 1).